![]() | |
Clinical data | |
---|---|
Trade names | Fetzima |
Other names | Levomilnacipran hydrochloride |
AHFS/ Drugs.com | Monograph |
Routes of administration | By mouth ( capsules) |
Drug class | Serotonin–norepinephrine reuptake inhibitor (SNRI) [1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 92% [2] |
Protein binding | 22% [3] |
Metabolism | Liver (primarily by CYP3A4) [4] |
Elimination half-life | 12 hours [4] |
Excretion | Kidney [4] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H22N2O |
Molar mass | 246.354 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant used to treat major depressive disorder. [1] While not approved for fibromyalgia, the similar medication milnacipran is. [1] It is taken by mouth. [1]
Common side effects include nausea, constipation, increased sweating, sexual dysfunction, and palpitations. [1] Other side effects may include suicide in those under 25 years, serotonin syndrome, high blood pressure, bleeding, mania, and urinary retention. [1] Safety in pregnancy is unclear. [5] It is a serotonin–norepinephrine reuptake inhibitor (SNRI) and an enantiomer of milnacipran. [1]
Levomilnacipran was approved for medical use in the United States in 2013 and Canada in 2015. [1] [6] Approval was rejected in Australia in 2016 and has not been applied for in Europe. [6] In the United States it cost about 430 USD per month as of 2021. [7]
![]() | |
Clinical data | |
---|---|
Trade names | Fetzima |
Other names | Levomilnacipran hydrochloride |
AHFS/ Drugs.com | Monograph |
Routes of administration | By mouth ( capsules) |
Drug class | Serotonin–norepinephrine reuptake inhibitor (SNRI) [1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 92% [2] |
Protein binding | 22% [3] |
Metabolism | Liver (primarily by CYP3A4) [4] |
Elimination half-life | 12 hours [4] |
Excretion | Kidney [4] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C15H22N2O |
Molar mass | 246.354 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Levomilnacipran, sold under the brand name Fetzima, is an antidepressant used to treat major depressive disorder. [1] While not approved for fibromyalgia, the similar medication milnacipran is. [1] It is taken by mouth. [1]
Common side effects include nausea, constipation, increased sweating, sexual dysfunction, and palpitations. [1] Other side effects may include suicide in those under 25 years, serotonin syndrome, high blood pressure, bleeding, mania, and urinary retention. [1] Safety in pregnancy is unclear. [5] It is a serotonin–norepinephrine reuptake inhibitor (SNRI) and an enantiomer of milnacipran. [1]
Levomilnacipran was approved for medical use in the United States in 2013 and Canada in 2015. [1] [6] Approval was rejected in Australia in 2016 and has not been applied for in Europe. [6] In the United States it cost about 430 USD per month as of 2021. [7]